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Valorisation
In a document published by McKinsey in 20131, it is stated that by 2040, due to 
increasing demand and supply of health care, roughly 25% of the Netherlands’ 
gross domestic product will be spent on its healthcare system. In pursuit of a 
sustainable and high quality health care system, health care managers were 
interviewed and bundled their thoughts in the following consensus: by 2040 the 
Netherlands should have the best possible health care system in the world, in 
term of quality and accessibility, while maintaining a fair balance between costs 
and returns, but most importantly the health care system emphasizes health 
and staying healthy. In other words, a health care system that particularly pro-
motes effective preventive measures instead of a narrow emphasis on cure. In 
general, this thesis focusses on early recognition and diagnosis of gastrointestinal 
manifestations in patients with diabetes mellitus and provides data supporting a 
sustainable health care system. 
Diabetes mellitus is a global health concern with a high and growing prevalence 
of about 9% in adults globally. Diabetes mellitus can be viewed as an economic 
burden with 12% of global health expenditure according to the international dia-
betes federation2. The global cost is predicted to approach 1,452 billion dollar by 
2040 due to the increased prevalence of risk factors for diabetes, such as obesity, 
and the ageing of the world’s population. Logically, diabetes mellitus is a chronic 
disease that needs the attention of health care managers and policymakers. In 
attempt to reduce diabetes incidence, numbers of trials have emerged and showed 
that type 2 diabetes mellitus can be prevented or even delayed through lifestyle 
programs or with timely start of metformin in pre-diabetic individuals3–5. Unfor-
tunately, up to this date, the ideal cost-effective translation of these programs 
into ‘real-world’ settings is not known and remains a major challenge6. It is clear, 
to prevent rising health care costs, diabetes incidence needs to be reduced by 
means of effective primary prevention strategies. In chapter 3 of this thesis, the 
intestinal barrier is reviewed in relation to diabetes mellitus development. When 
current preventive strategies fail or need improvement, inspiration could be de-
rived from new insights. In chapter 3 we conclude that more understanding of 
the intestinal barrier could have important clinical implications by potentially 
opening new horizons in the treatment and prevention of diabetes mellitus. For 
instance, future therapeutic drugs or specific diets that focus on enhancing the 
intestinal barrier function could be a part in the prevention strategies regarding 
metabolic diseases such as diabetes mellitus.  
However, once diabetes mellitus is an established disease, focus must shift to-
wards controlling the disease and preventing costly but also disabling diabetic 
complications such as vascular diseases, nephropathy and retinopathy. This the-
sis focusses on the less notorious but equally relevant gastrointestinal manifes-
tations of diabetes mellitus. In chapter 2 of this thesis, we observed a significantly 
increased prevalence of the gastrointestinal symptoms diarrhea, bloating and 
early satiety, but also of anxiety and depression in patients with type 2 diabetes 
mellitus. The importance of viewing gastrointestinal and psychological symptoms 
simultaneously, as factors that can influence each other in either direction, is 
emphasized and considered relevant for physicians treating patients with diabetes. 
Early recognition and treatment initiation of these symptoms is key as studies 144
show that gastrointestinal complaints impact work productivity and is associated 
with absenteeism7 and effective treatment improves productivity8.  
The major part of this thesis focusses on the association between diabetes mel-
litus and colorectal cancer. Colorectal cancer is the third most common cancer 
in men (~10%) and the second in women (~9%) with a mortality rate of 8.3 per 
100,000 person years. In 2011 in the Netherlands, the costs of colorectal cancer 
care accumulated up to 488 million euro which contributed to ~10% of all cancer 
related health care costs9. Considering these numbers, it may be said that colo-
rectal cancer has major impact on healthcare costs and certainly on the popula-
tion’s health in general. Currently, the colorectal cancer incidence rates are sta-
bilizing and are expected to decrease in countries where population based CRC 
screening has been implemented. 
Studies confirm the effectiveness of screening of the average risk population with 
colonoscopy and performing polypectomy in preventing colorectal cancer10. 
Colorectal cancer screening has recently (2014) been implicated in the Netherlands 
and the definite yield in terms of colorectal cancer incidence and mortality re-
duction has yet to be observed by the Dutch cancer registries. Since screening 
and surveillance programs are costly in terms of money and workforce the cost-
effectiveness should be hold in account continually. One way of increasing effec-
tiveness of colorectal screening programs is by screening those individuals at 
higher risk for colorectal cancer. 
In this thesis, a moderate increased prevalence of colorectal adenomas (chapter 6) 
and incidence of colorectal cancer (chapter 4) in T2DM was observed. In chapter 
7 of this thesis, particularly young individuals with type 2 diabetes mellitus ap-
peared at higher colorectal cancer risk compared to their peers without diabetes. 
In chapter 7, a young diabetic patient was defined by a diagnosis of diabetes be-
fore the age of 55 years, the age at which individuals are enrolled in the colorectal 
cancer screening program. An earlier initiation of CRC screening in individuals 
with type 2 diabetes mellitus may be cost-effective. In the discussion section of 
this thesis, based on current colorectal cancer crude incidence rates, as reported 
by the Netherlands Comprehensive Cancer Organization, a simple calculation 
showed that the crude incidence of colorectal cancer in men and women with 
diabetes aged 50 to 54 years is comparable with the colorectal cancer incidence 
in the general population aged 55 to 59 years. This comparability in CRC incidence 
suggests that the FIT test, used in the current screening program, could harbor 
the same diagnostic yield. 
Defining a high(er) risk subpopulation to screen is one way of optimizing screening 
strategies. Another way is to improve the effectiveness of the instruments used 
in the screening program. For instance, in chapter 6 of this thesis we have docu-
mented that individuals with diabetes that underwent a colonoscopy more often 
had an inadequate bowel preparation as compared to controls without diabetes. 
Paying attention to risk factors associated with an inadequate bowel preparation 
in pre-colonoscopy interviews followed by simple adjustments may help to improve 
adenoma detection and polyp removal11. Moreover, expensive and time-consuming 
repetitions of colonoscopies may be prevented. 145
In the future, we may be able to focus even more on the risk of the individual. 
For instance, personalized risk-based colorectal screening for which question-
naires and biological samples can be used to collect data from large groups of 
the population. This data can be used to unveil risk factors, their risk factor in-
teractions, and categorize individuals into predefined risk categories (e.g. high 
risk vs. intermediate vs. low risk).  
Epigenetic markers can be used to define a part of the colorectal cancer risk 
profile. Numerous SNP’s have been reported to be associated with increased 
risk of developing colorectal cancer. It is very plausible that other types of bio-
markers, like serum proteins of hormones of interest will be found. In chapter 5 
of this thesis we observed an increased colorectal cancer risk in individuals with a 
genetic variation in the IGF pathway, which was more pronounced in individuals 
with diabetes mellitus. Studies like the one in chapter 5 could revalue phenotypic 
risk factors by means of genetic profiling. 
In terms of screening, a political trade-off is made between benefits (e.g. life years 
gained), harms (e.g. colon perforation) and costs. A study has pointed out in micro-
simulation models that screening based on risk stratification can particularly 
reduce harms. As false positives outcomes are consistently lower with this 
method12. On the one hand the costs of defining risk categories in screening can 
be expected to increase with available biodata. On the other hand, individuals 
needing diagnostic investigations, such as colonoscopies, are reduced up to ~25% 
according to one published model13, which in turn could reduce the screening costs.
In summary, we should pursue a sustainable future health care that particularly 
promotes effective preventive measures instead of adhering to a narrow emphasis 
on cure. This thesis can add to the knowledge needed for effective early inter-
ventions or even prevent the gastrointestinal complications associated with 
diabetes mellitus.
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